On March 1, 2022 Molecular Templates, Inc. (Nasdaq: MTEM, "Molecular Templates" or "MTEM"), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, reported that it will participate in several upcoming investor conferences (Press release, Molecular Templates, MAR 1, 2022, View Source [SID1234609303]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details can be found below:

Cowen’s 42nd Annual Health Care Conference (March 7-9, 2022)
Format:
Corporate Presentation
Date: Tuesday, March 8th
Time: 10:30 AM – 11:00 AM ET

Oppenheimer’s 32nd Annual Healthcare Conference (March 15-16, 2022)
Format:
Corporate Presentation
Date: Wednesday, March 16
Time: 2:00 PM – 2:30 PM ET

Barclays Global Healthcare Conference 2022 (March 15-17, 2022)
Format:
Corporate Presentation
Date: Tuesday, March 15
Time: 4:20 PM – 4:45 PM ET
Webcast links for the presentations will be posted on the "News and Media" section of the Molecular Templates corporate website, under Events.

On March 1, 2022 Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, reported that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will present and host one-on-one meetings at Oppenheimer’s 32nd Annual Healthcare Conference (Press release, Aptose Biosciences, MAR 1, 2022, View Source [SID1234609302]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Aptose Presentation – Oppenheimer’s 32nd Annual Healthcare Conference
Date: Tuesday, March 15, 2022
Time: 10:00 – 10:30 ET
Format: Virtual
Webcast: Link
The audio webcast also will be accessible through the Aptose website at www.aptose.com and will be archived shortly after the live events.

On March 1, 2022 XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, reported its Chairman and Chief Executive Officer, Jim Neal, will be featured in a fireside chat at the 42nd Annual Cowen Health Care Conference on Monday, March 7, 2022, at 1:30 PM ET (Press release, Xoma, MAR 1, 2022, View Source [SID1234609301]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation can be accessed at https://bit.ly/3rPGmLl or by visiting the investor relations section of the Company’s website at www.xoma.com. A replay of the presentation will be available and archived on the site for 90 days after the event.

On March 1, 2022 iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, reported that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 12:50 p.m. ET (Press release, iTeos Therapeutics, MAR 1, 2022, https://investors.iteostherapeutics.com/news-releases/news-release-details/iteos-present-cowen-42nd-annual-health-care-conference [SID1234609300]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the virtual presentation will be available on the Investors section of the company’s website at View Source An archived replay will be available for approximately 30 days following the presentation.

On March 1, 2022 BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, reported that the Company will participate in the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 9:50 a.m. ET (Press release, BeiGene, MAR 1, 2022, View Source [SID1234609299]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast can be accessed from the investors section of BeiGene’s website at View Source or View Source An archived replay will be available for 90 days following the event.